Concepedia

Author

Daniela Gmehling

University of Freiburg

Also Known As

D. Gmehling, Daniela Gmehling

6

Publications

349

Citations

6

H-Index

14

Concepts

All Affiliations

University of FreiburgBoehringer Ingelheim (Germany)Bayer (Germany)
DG

About

Daniela Gmehling is an author at University of Freiburg specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

140

2

Pharmacology

3

3

140

3

Cancer Therapeutics

2

2

41

4

Pathology

1

1

15

5

Clinical Pharmacology

1

1

99

Daniela Gmehling

×

6

Publications

349

Citations

6

H-Index

YearCitations

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

K. Mross, Martin Štefanič, Daniela Gmehling,

Clinical Cancer Research

2009

164

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib

K. Mross, Simone Steinbild, F. Baas,

European Journal of Cancer

2006

99

A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients

K. Mross, Daniela Gmehling, Annette Frost,

Journal of Clinical Oncology

2005

26

Lack of inducible nitric oxide synthase activity in T cell clones and T lymphocytes from naive and <i>Leishmania major</i>‐infected mice

H Thüring, Steffen Stenger, Daniela Gmehling,

European Journal of Immunology

1995

24

Treatment of Anthracycline Extravasation with Dexrazoxane – Clinical Experience

Annette Frost, Daniela Gmehling, Marc Azémar,

Oncology Research and Treatment

2006

21

Phase I study of BAY 43–9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

Simone Steinbild, F. Baas, Daniela Gmehling,

Journal of Clinical Oncology

2005

15

Page 1